Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3444624 | 0.91 | LMNA (0.52) | KCNH2MAPTTSHRHTR7ALDH1A1 | |
| SCHEMBL3445070 | 0.91 | MEN1 (0.51) | KCNH2MAPTTSHRHTR7RECQL | |
| SCHEMBL3445355 | 0.88 | MEN1 (0.56) | MAPTTSHRALDH1A1MAPK1RECQL | |
| SCHEMBL3444483 | 0.87 | MAPT (0.50) | MAPTTSHRHTR7MAPK1RECQL | |
| SCHEMBL3444291 | 0.86 | MEN1 (0.47) | MAPTTSHRHTR7SMN1; SMN2RECQL | |
| SCHEMBL3443532 | 0.86 | IGF1R (0.48) | MAPTTSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3444171 | 0.86 | MEN1 (0.53) | KCNH2MAPTTSHRHTR7MAPK1 | |
| SCHEMBL3443523 | 0.84 | MAPT (0.48) | MAPTTSHRHTR7MAPK1RECQL | |
| SCHEMBL3443537 | 0.84 | MEN1 (0.48) | KCNH2MAPTTSHRHTR7RECQL | |
| SCHEMBL3444821 | 0.83 | HRH4 (0.49) | KCNH2MAPTSMN1; SMN2DRD2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390812-B2 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2008-06-24 | — | — | US | claimed |
| EP-1496904-B1 | USE OF PHARMACEUTICALS CONTAINING N, N'-DISUBSTITUTED PIPERAZINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-08-15 | — | — | EP | claimed |
| EP-1492781-B1 | N,N'-DISUBSTITUTED PIPERAZINE COMPOUNDS AND THE USE OF THE SAME AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2006-03-08 | — | — | EP | claimed |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | GRUNENTHAL GMBH (DE) | 2005-02-17 | — | — | US | claimed |
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-7816358-B2 | Pharmaceutical formulations comprising N,N′-disubstituted piperazine compounds | GRUENENTHAL GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7390812-B2 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1496904-B1 | USE OF PHARMACEUTICALS CONTAINING N, N'-DISUBSTITUTED PIPERAZINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1492781-B1 | N,N'-DISUBSTITUTED PIPERAZINE COMPOUNDS AND THE USE OF THE SAME AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | GRUNENTHAL GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | OPRL1, OPRK1, OPRM1 | KCNH2 365/4885MAPT 1180/4885TSHR 4067/4885 |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNT, AANAT | KCNH2 806/4885MAPT 666/4885TSHR 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.